Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect
Release Notes Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
PMP
MCID: PSD007
MIFTS: 52

Pseudomyxoma Peritonei (PMP)

Categories: Cancer diseases, Gastrointestinal diseases, Rare diseases
Data Licensing
For inquiries, contact:
[email protected]
Genes Tissues Related diseases Publications Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Pseudomyxoma Peritonei

About this section

MalaCards integrated aliases for Pseudomyxoma Peritonei:

Name: Pseudomyxoma Peritonei 11 19 58 75 53 43 14 16 71
Gelatinous Ascites 19 58
Adenomucinosis 19 58
Pmp 19 58
Syndrome of Pseudomyxoma Peritonei 19
Mucinous Ascites 11

Characteristics:


Prevelance:

1-9/1000000 (Worldwide, Netherlands) 1-9/100000 (Europe) 58

Age Of Onset:

Adult 58

Classifications:

MalaCards categories:
Global: Rare diseases Cancer diseases
Anatomical: Gastrointestinal diseases
See all MalaCards categories (disease lists)
ICD10: 32


External Ids:

Disease Ontology 11 DOID:3559
MeSH 43 D011553
NCIt 49 C3345
SNOMED-CT 68 307601000
MESH via Orphanet 44 D011553
ICD10 via Orphanet 32 C78.6
UMLS via Orphanet 72 C0033822
Orphanet 58 ORPHA26790
UMLS 71 C0033822
Sources

Summaries for Pseudomyxoma Peritonei

About this section

GARD: 19 Pseudomyxoma peritonei (PMP) is a rare disease characterized by the presence of mucin in the abdominal (peritoneal) cavity. While the most common cause of PMP is appendix cancer, several types of tumors (including non-cancerous tumors) can cause PMP. Signs and symptoms may include an increase in abdominal size or bloating; inguinal hernia (in men); an ovarian mass that may be felt during a routine pelvic exam (in women); pain or discomfort in the abdomen; and/or appendicitis.

MalaCards based summary: Pseudomyxoma Peritonei, also known as gelatinous ascites, is related to intestinal obstruction and appendiceal neoplasm. An important gene associated with Pseudomyxoma Peritonei is KRT7 (Keratin 7), and among its related pathways/superpathways are Disease and fMLP Pathway. The drugs Cisplatin and Thalidomide have been mentioned in the context of this disorder. Affiliated tissues include appendix, small intestine and colon, and related phenotypes are ascites and abnormality of the peritoneum

Orphanet: 58 Pseudomyxoma peritonei is characterized by disseminated intra-peritoneal mucinous tumors and mucinous ascites in the abdomen and pelvis.

Disease Ontology: 11 An appendix cancer that is characterized by progressive accumulation of mucus-secreting tumor cells within the abdomen and pelvis.

Wikipedia: 75 Pseudomyxoma peritonei (PMP) is a clinical condition caused by cancerous cells (mucinous adenocarcinoma)... more...
Sources

Related Diseases for Pseudomyxoma Peritonei

About this section

Diseases related to Pseudomyxoma Peritonei via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 610)
# Related Disease Score Top Affiliating Genes
1 intestinal obstruction 30.9 KRT7 KRT20 CEACAM5 CDX2
2 appendiceal neoplasm 30.9 KRT7 KRAS GNAS CEACAM5 CDX2
3 benign mesothelioma 30.8 KRT7 KRT20 CEACAM5
4 mucinous ovarian cystadenoma 30.7 KRT7 KRT20 CEACAM5 CDX2
5 appendix adenocarcinoma 30.6 TP53 KRT7 KRT20 KRAS GNAS CEACAM5
6 colloid carcinoma of the pancreas 30.5 MUC5AC CDX2
7 bladder urachal carcinoma 30.4 REG4 KRT7 KRAS CDX2
8 endometrial mucinous adenocarcinoma 30.4 KRAS GNAS
9 mucinous cystadenocarcinoma 30.4 MUC16 MUC1 KRT7 KRT20 KRAS CEACAM5
10 mucinous cystadenocarcinoma of pancreas 30.3 MUC6 CEACAM5
11 benign teratoma 30.3 TP53 KRT7 KRT20 CEACAM5 CDX2
12 tuberculous peritonitis 30.2 MUC16 CEACAM5
13 transverse colon cancer 30.2 KRT20 KRAS CEACAM5
14 peritoneal mesothelioma 30.2 TP53 KRT7 EPCAM CEACAM5
15 ovarian cyst 30.2 MUC16 MUC1 GNAS CEACAM5
16 endometrial adenocarcinoma 30.1 TP53 KRT7 KRAS
17 ovarian mucinous adenocarcinoma 30.1 MUC5AC KRT7 KRT20 CEACAM5 CDX2
18 rectum cancer 30.1 TP53 KRT20 KRAS CEACAM5
19 krukenberg carcinoma 30.1 KRT7 KRT20 CEACAM5 CDX2
20 cystic teratoma 30.0 TP53 MUC1 KRT7 KRT20 CEACAM5 CDX2
21 cystadenocarcinoma 30.0 TP53 MUC5AC MUC2 MUC16 MUC1 KRT7
22 cholangitis 30.0 TP53 KRT7 CEACAM5
23 adenomyoma 29.9 MUC1 KRT7 CTNNB1
24 myoma 29.9 TP53 KRAS CEACAM5
25 cystadenoma 29.9 REG4 MUC6 MUC5AC MUC16 MUC1 KRT7
26 ovarian mucinous neoplasm 29.9 MUC6 MUC5AC KRT7 KRT20 KRAS CEACAM5
27 goblet cell carcinoid 29.9 KRT20 CTNNB1 CDH1
28 mucinous adenocarcinoma 29.8 TP53 MUC6 MUC5AC MUC1 KRT7 KRT20
29 urinary tract obstruction 29.8 KRT7 CTNNB1 CDH1
30 mature teratoma 29.8 TP53 KRT7 CEACAM5 CDX2
31 ovarian cystadenoma 29.7 TP53 MUC16 KRT7 CEACAM5
32 pancreatic adenocarcinoma 29.6 TP53 KRAS GNAS CTNNB1
33 diffuse gastric cancer 29.6 TP53 KRAS CTNNB1 CDH1
34 peritoneum cancer 29.6 TP53 KRT7 EPCAM CEACAM5
35 endometrial hyperplasia 29.4 TP53 KRAS CTNNB1
36 cholangitis, primary sclerosing 29.3 TP53 KRT7 KRAS EPCAM CEACAM5
37 adenocarcinoma in situ 29.3 TP53 MUC6 KRT7 KRAS CEACAM5 CDX2
38 rectal benign neoplasm 29.2 TP53 KRT7 KRT20 KRAS CTNNB1 CEACAM5
39 microinvasive gastric cancer 29.2 TP53 MUC6 MUC5AC CEACAM5 CDX2 CDH1
40 teratoma 29.1 TP53 MUC1 KRT7 KRT20 KRAS CTNNB1
41 endocervical adenocarcinoma 29.1 TP53 MUC6 KRT7 CTNNB1 CEACAM5
42 colorectal adenoma 29.0 TP53 KRAS CTNNB1 CEACAM5 CDH1
43 gallbladder disease 28.8 TP53 KRT7 KRAS CTNNB1 CEACAM5 CDH1
44 mesothelioma, malignant 28.8 MUC16 MUC1 KRT7 KRT20 CTNNB1 CEACAM5
45 adenoma 28.7 TP53 MUC6 MUC5AC MUC1 KRT7 KRT20
46 colon adenocarcinoma 28.7 TP53 KRT20 KRAS GNAS CTNNB1 CEACAM5
47 adenocarcinoma 28.6 TP53 MUC5AC MUC1 KRT7 KRT20 KRAS
48 villous adenoma 28.5 TP53 MUC6 MUC5AC KRT7 KRAS GNAS
49 colorectal adenocarcinoma 28.5 TP53 KRT7 KRT20 KRAS CTNNB1 CEACAM5
50 appendix cancer 28.3 TP53 REG4 MUC6 MUC5AC MUC1 KRT7

Graphical network of the top 20 diseases related to Pseudomyxoma Peritonei:



Diseases related to Pseudomyxoma Peritonei
Sources

Symptoms & Phenotypes for Pseudomyxoma Peritonei

About this section

Human phenotypes related to Pseudomyxoma Peritonei:

58 30 (show all 12)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 ascites 58 30 Hallmark (90%) Very frequent (99-80%)
 HP:0001541
2 abnormality of the peritoneum 58 30 Hallmark (90%) Very frequent (99-80%)
 HP:0002585
3 abnormality of the abdominal wall 58 30 Hallmark (90%) Very frequent (99-80%)
 HP:0004298
4 inflammation of the large intestine 58 30 Frequent (33%) Frequent (79-30%)
 HP:0002037
5 nausea and vomiting 58 30 Occasional (7.5%) Occasional (29-5%)
 HP:0002017
6 constipation 58 30 Occasional (7.5%) Occasional (29-5%)
 HP:0002019
7 respiratory insufficiency 58 30 Occasional (7.5%) Occasional (29-5%)
 HP:0002093
8 hernia 58 30 Occasional (7.5%) Occasional (29-5%)
 HP:0100790
9 abdominal pain 58 30 Occasional (7.5%) Occasional (29-5%)
 HP:0002027
10 weight loss 58 30 Occasional (7.5%) Occasional (29-5%)
 HP:0001824
11 intestinal obstruction 58 30 Occasional (7.5%) Occasional (29-5%)
 HP:0005214
12 lymphadenopathy 58 30 Occasional (7.5%) Occasional (29-5%)
 HP:0002716

MGI Mouse Phenotypes related to Pseudomyxoma Peritonei:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.03 CDH1 CDX2 CEACAM5 CTNNB1 EPCAM GNAS
2 neoplasm MP:0002006 10.02 CDH1 CDX2 CEACAM5 CTNNB1 GNAS KRAS
3 no phenotypic analysis MP:0003012 9.87 CDH1 CTNNB1 EPCAM GNAS KRAS MUC1
4 endocrine/exocrine gland MP:0005379 9.85 CDH1 CDX2 CEACAM5 CTNNB1 EPCAM GNAS
5 digestive/alimentary MP:0005381 9.7 CDH1 CDX2 CEACAM5 CTNNB1 EPCAM GNAS
6 cellular MP:0005384 9.32 CDH1 CDX2 CEACAM5 CTNNB1 EPCAM GNAS
Sources

Drugs & Therapeutics for Pseudomyxoma Peritonei

About this section

Drugs for Pseudomyxoma Peritonei (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 62)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cisplatin Approved Phase 2 15663-27-1 2767 5702198 441203
2
Thalidomide Approved, Investigational, Withdrawn Phase 2 50-35-1 5426
3
Capecitabine Approved, Investigational Phase 2 154361-50-9 60953
4
Nivolumab Approved Phase 2 946414-94-4
5
Ipilimumab Approved Phase 2 477202-00-9
6
Amoxicillin Approved, Vet_approved Phase 2 26787-78-0 33613
7
Carbamide peroxide Approved Phase 2 124-43-6
8
Dexlansoprazole Approved, Investigational Phase 2 138530-94-6 9578005
9
Lansoprazole Approved, Investigational Phase 2 103577-45-3 3883
10
Clarithromycin Approved Phase 2 81103-11-9 84029
11
Acetylcysteine Approved, Investigational Phase 2 616-91-1 581 12035
12
Fluorouracil Approved Phase 2 51-21-8 3385
13
Levoleucovorin Approved, Experimental, Investigational Phase 2 68538-85-2, 58-05-9, 73951-54-9 149436 6006
14
Oxaliplatin Approved, Investigational Phase 2 61825-94-3 43805 11947679 6857599
15
Folic acid Approved, Nutraceutical, Vet_approved Phase 2 59-30-3 6037
16 Alkylating Agents Phase 2
17 Angiogenesis Inhibitors Phase 2
18 Cola Phase 2
19 Immunoglobulins Phase 2
20 Immune Checkpoint Inhibitors Phase 2
21 Antibodies, Monoclonal Phase 2
22 Antibodies Phase 2
23 Antineoplastic Agents, Immunological Phase 2
24 Antibiotics, Antitubercular Phase 2
25 Anti-Ulcer Agents Phase 2
26 Anti-Bacterial Agents Phase 2
27 Antacids Phase 2
28 Proton Pump Inhibitors Phase 2
29 Cytochrome P-450 Enzyme Inhibitors Phase 2
30 Gastrointestinal Agents Phase 2
31 Cytochrome P-450 CYP3A Inhibitors Phase 2
32 Anti-Infective Agents Phase 2
33 Antiviral Agents Phase 2
34 Expectorants Phase 2
35 N-monoacetylcystine Phase 2
36 Respiratory System Agents Phase 2
37 Antioxidants Phase 2
38 Antimetabolites Phase 2
39 Vitamins Phase 2
40 Folate Phase 2
41 Vitamin B9 Phase 2
42 Trace Elements Phase 2
43 Vitamin B Complex Phase 2
44 Antidotes Phase 2
45 Immunosuppressive Agents Phase 2
46 Micronutrients Phase 2
47 Immunologic Factors Phase 2
48 Protective Agents Phase 2
49
Irinotecan Approved, Investigational Phase 1 97682-44-5, 100286-90-6 60838
50
Carboplatin Approved Phase 1 41575-94-4 10339178 38904

Interventional clinical trials:

(show all 27)
# Name Status NCT ID Phase Drugs
1 Single Arm Study Treating Patients of Peritoneal Surface Malignancy (Colorectal, Appendical, Pseudomyxoma, Gastric) With Cytoreductive Surgery and Hyperthermic Intraperitoneal Mitomycin-C Completed NCT02040142 Phase 2 Mitomycin C
2 Effects of High Intra-abdominal Pressure on Tissue Diffusion and Pharmacokinetics of Cisplatin During HIPEC Completed NCT02949791 Phase 2
3 Phase II Trial of Adjuvant Thalidomide Following Cytoreductive Surgery and Intraperitoneal Hyperthermic Chemotherapy for Peritoneal Carcinomatosis or Adenomucinosis From Colorectal/Appendiceal Cancer Completed NCT00310076 Phase 2 thalidomide
4 Adjuvant CAPECITABINE in High Risk PSEUDOMYXOMA PERITONEI Patients Treated With CYTOREDUCTIVE SURGERY (CRS) and HYPERTERMIC INTRAPERITONEAL CHEMOTHERAPY (HIPEC) Recruiting NCT05321329 Phase 2 Capecitabine
5 DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors Recruiting NCT02834013 Phase 2
6 Clinical Trial to Define the Effect of Perioperative H. Pylori Eradication With Antibiotic Treatment on Long Term Outcomes of Patients With Pseudomyxoma Peritonei of Appendiceal Origin Undergoing Cytoreductive Surgery/Hyperthermic Intraperitoneal Chemotherapy Active, not recruiting NCT02387203 Phase 2 PrevPac (Prevacid, Amoxicillin, Clarithromycin)
7 A Phase 2, Multi-centre Study of BromAc for Recurrent Peritoneal Mucinous Tumour or Pseudomyxoma Peritonei Not yet recruiting NCT03976973 Phase 2 Bromelain;Acetylcysteine
8 A Phase II Study of Surgical Debulking With Peritonectomy and Biweekly Intraperitoneal 5FU With Systemic Oxaliplatin/5FU/Leucovorin in Patients With Pseudomyxoma Peritonei or Peritoneal Carcinomatosis Terminated NCT00352755 Phase 2 Intraperitoneal 5FU;FOLFOX
9 Phase I Trial of Cytoreductive Surgery and Heated Intraperitoneal Chemotherapy With Nanoliposomal Irinotecan in Patients With Peritoneal Surface Malignancies Completed NCT04088786 Phase 1 nanoliposomal irinotecan
10 A Phase 1 Study of Carboplatin and Gemcitabine Chemotherapy and Stereotactic Body Radiosurgery for the Palliative Treatment of Persistent or Recurrent Gynecologic Cancer Completed NCT01652794 Phase 1 carboplatin;gemcitabine hydrochloride
11 A Phase 1 Study of SGN-STNV in Advanced Solid Tumors Recruiting NCT04665921 Phase 1 SGN-STNV
12 Intratumoral Bromelain + N-acetylcysteine in Relapsed and Unresectable Pseudomyxoma Peritonei. Phase I Single-arm Trial Active, not recruiting NCT04982146 Phase 1 Bromelin;N-Acetylcysteine
13 Comparison Between Cyotreductive Surgery and Debulking Surgery in Patients With Pseudomyxoma Peritonei Unknown status NCT01427101
14 Multicenter, International Online Documentation of Indications and Results of Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC Und PITAC) for Treating Malignant Peritoneal and Pleural Diseases Unknown status NCT03210298
15 French National Registry of Rare Peritoneal Surface Malignancies (RENAPE Registry) Unknown status NCT02834169
16 Thrombin Generation and Platelet Activation in Cytoreductive Surgery Combined With Hyperthermic Intraperitoneal Chemotherapy Completed NCT03034850
17 A Survey of the Knowledge, Attitudes, and Practice of Surgeons Toward Nutrition Support in HIPEC Patients Completed NCT02374411
18 HOPE Program: Quality of Life Enhancement and Survivorship Care Completed NCT01126346
19 A Biobehavioral Intervention for Patients With Gynecologic or Breast Cancer Recurrence Completed NCT01764789
20 A Randomized Crossover Trial of Systemic Chemotherapy in Patients With Metastatic Well-Differentiated Mucinous Appendiceal Adenocarcinomas With Pseudomyxoma Peritonei Recruiting NCT01946854
21 A Cohort Study of the Gastrointestinal Microbiome in Appendiceal Cancer With Peritoneal Spread Recruiting NCT02599116
22 Prospective Observational Study of Peritoneal Surface Malignancies (PSM) - Characterization, Models and Treatment Strategies. Recruiting NCT02073500
23 A Phase II Trial to Analyze Clinical and Pharmacological Properties for Severe Neutropenia After Cytoreductive Surgery Followed by Hyperthermic Intraperitoneal Chemotherapy Using Mitomycin-C Recruiting NCT05513183
24 Register With Data From Patients With the Diagnosis of a Peritoneal Surface Malignancy, for Which Cytoreductive Surgery and Hyperthermic Intra-Peritoneal Chemotherapy (HIPEC) is Performed Recruiting NCT01617382
25 Implementation of a Cardiac Coherence Program to Reduce Anxiety in Patients With Peritoneal Carcinosis Treated by Surgery: Randomized Pilot Study Recruiting NCT04024917
26 Recovery of Quality of Life After Cytoreductive Surgery and Intraperitoneal Chemotherapy for Colorectal Cancer and Pseudomyxoma Peritonei Not yet recruiting NCT03503071
27 An Interpretative Phenomenological Analysis of 'Recovery' Following Complete Cytoreductive Surgery. Withdrawn NCT04125225

Search NIH Clinical Center for Pseudomyxoma Peritonei

Cochrane evidence based reviews: pseudomyxoma peritonei

Sources

Genetic Tests for Pseudomyxoma Peritonei

About this section
Sources

Anatomical Context for Pseudomyxoma Peritonei

About this section

Organs/tissues related to Pseudomyxoma Peritonei:

MalaCards : Appendix, Small Intestine, Colon, Breast, Ovary, Lymph Node, Spleen
Sources

Publications for Pseudomyxoma Peritonei

About this section

Articles related to Pseudomyxoma Peritonei:

(show top 50) (show all 1650)
# Title Authors PMID Year
1
CDX-2 expression in pseudomyxoma peritonei: a clinicopathological study of 42 cases. 53 62
16978201 2006
2
MUC2 is a molecular marker for pseudomyxoma peritonei. 53 62
12218214 2002
3
Pseudomyxoma peritonei is a disease of MUC2-expressing goblet cells. 53 62
12163380 2002
4
Mucinous tumors of the vermiform appendix and ovary, and pseudomyxoma peritonei: histogenetic implications of cytokeratin 7 expression. 53 62
9308728 1997
5
Immunohistochemical study of cytokeratin 7 for the differential diagnosis of adenocarcinomas in the ovary. 53 62
7506222 1993
6
ASO Author Reflections: Incomplete Cytoreduction Prediction Model for Pseudomyxoma Peritonei. 62
34549365 2022
7
First Report With Medium Term Follow Up Of Intestinal Transplantation For Advanced And Recurrent Non-Resectable Pseudomyxoma Peritonei. 62
36468404 2022
8
[Current treatment recommendations for pseudomyxoma peritonei]. 62
36097078 2022
9
High-Grade Appendiceal Mucinous Neoplasm: Clinicopathologic Findings in 35 Cases. 62
35472721 2022
10
[54/m-Mucinous ascites : Preparation for the medical specialist examination: part 16]. 62
36053320 2022
11
Clinicopathologic parameters and outcomes of mucinous neoplasms confined to the appendix: a benign entity with excellent prognosis. 62
35676331 2022
12
Combined ultrasonography and CT for prognosis and predicting clinical outcomes of patients with pseudomyxoma peritonei. 62
36418618 2022
13
Cytoreductive surgery and concomitant hyperthermic thoracoabdominal chemotherapy for pseudomyxoma peritonei with abdominal and pleural involvement. 62
35170171 2022
14
An unusual life-threatening case of appendiceal pseudomyxoma peritonei (PMP) mimicking sigmoid volvulus. 62
36377767 2022
15
Prevalence and incidence of pseudomyxoma peritonei in urban China: A nationwide retrospective cohort study. 62
35764460 2022
16
Preoperative plasma D-Dimer level is correlated with peritoneal cancer index of patients with pseudomyxoma peritonei. 62
36316677 2022
17
Rapid recurrence of a ruptured mucinous borderline ovarian tumor harboring K-RAS mutation followed by progression into anaplastic carcinoma with TP53 mutation. 62
36281401 2022
18
The Impact of Low Skeletal Muscle Mass on Short- and Long-Term Outcomes After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy. 62
35650370 2022
19
Low-Grade Appendiceal Mucinous Neoplasm: A Case Series. 62
36211097 2022
20
Preoperative systemic chemotherapy does not benefit for appendiceal pseudomyxoma peritonei. 62
36136728 2022
21
Scalloping of the Liver and Spleen on Preoperative CT-Scan of Pseudomyxoma Peritonei Patients: Impact on Prediction of Resectability, Grade, Morbidity and Survival. 62
36139595 2022
22
Clinical significance of laparoscopic cytoreductive surgery for appendiceal pseudomyxoma peritonei with limited disease and low tumor burden. 62
36064480 2022
23
ASO Author Reflections: Management of Recurrent Pseudomyxoma Peritonei After Cytoreductive Surgery and HIPEC. 62
36085391 2022
24
Relapse of Pseudomyxoma Peritonei After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy: Pattern of Failure, Clinical Management and Outcomes. 62
36094689 2022
25
A Case Report of Pseudomyxoma Peritonei Arising From Primary Mucinous Ovarian Neoplasms. 62
36277572 2022
26
Initial Experience of Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Baltic Country Center. 62
36233421 2022
27
Chronic Kidney Disease, Hypokalemia, and Appendicular Mucocele in a 66-Year-Old Man. 62
36154522 2022
28
Appendiceal mucocele with pseudomyxoma peritonei mimicking ovarian tumor with peritoneal carcinomatosis. 62
35755120 2022
29
Comprehensive Treatment Algorithms of the Swiss Peritoneal Cancer Group for Peritoneal Cancer of Gastrointestinal Origin. 62
36077810 2022
30
Beware of lethal Wernicke's encephalopathy after cytoreductive surgery with HIPEC for peritoneal pseudomyxoma: Case report of morbidity and mortality review. 62
36029660 2022
31
Clinical epidemiology of peritoneal metastases in China: The construction of professional peritoneal metastases treatment centers based on the prevalence rate. 62
36064631 2022
32
Giant bilateral intrathoracic involvement from pseudomyxoma peritonei. 62
35984225 2022
33
Survival prediction by Bayesian network modeling for pseudomyxoma peritonei after cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy. 62
36054637 2022
34
Diagnostic performance of positron emission tomography in the staging of pseudomyxoma peritonei. 62
35148916 2022
35
Pseudomyxoma peritonei with peristomal skin metastasis. 62
34714931 2022
36
Mucinous appendiceal neoplasms and pseudomyxoma peritonei: Morphological and clinical findings, differential diagnosis, and prognosis. 62
35900483 2022
37
Lymph node positive pseudomyxoma peritonei. 62
35941031 2022
38
Early postoperative intraperitoneal chemotherapy (EPIC) following cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) in 632 patients with pseudomyxoma peritonei of appendiceal origin: A single institution experience. 62
35168851 2022
39
Systemic metastases from low-grade and high-grade pseudomyxoma peritonei: Treatments and outcomes. 62
35090796 2022
40
Staging of appendiceal mucinous neoplasms: challenges and recent updates. 62
35843338 2022
41
Laparoscopic cytoreductive surgery and HIPEC in LAMN with small volume of peritoneal disease: a valuable option of treatment for good patient-related experience measures (PREMs). 62
34845545 2022
42
Recurrence of initially localized appendiceal mucinous neoplasms after radical resection: survey analysis and literature review. 62
35262818 2022
43
Progression to pseudomyxoma peritonei in patients with low grade appendiceal mucinous neoplasms discovered at time of appendectomy. 62
34879923 2022
44
Incidental Finding of Appendiceal Mucinous Neoplasm After Trauma: A Case Report. 62
35836463 2022
45
Prognostic Impact of Pathology, Cytoreduction, and Tumor Markers in Pseudomyxoma Peritonei. 62
35123285 2022
46
Peritoneal Pathology Review: Mullerian, Mucinous and Mesothelial Lesions. 62
35715161 2022
47
Prognostic value of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio on low-grade appendiceal mucinous neoplasm: A single tertiary hospital experience. 62
35421867 2022
48
Huge and Unique Pseudomyxoma Peritonei. 62
33679016 2022
49
Bedside Intraperitoneal Chemotherapy for Recurrent Pseudomyxoma Peritonei, an Alternative to Current Methods in a Low-Resource Tertiary Center. 62
35704528 2022
50
Pseudomyxoma peritonei involving the canal of Nuck: The added value of magnetic resonance imaging for detection and presurgical planning. 62
35401905 2022
Sources

Variations for Pseudomyxoma Peritonei

About this section
Sources

Expression for Pseudomyxoma Peritonei

About this section
Search GEO for disease gene expression data for Pseudomyxoma Peritonei.
Sources

Pathways for Pseudomyxoma Peritonei

About this section

Pathways related to Pseudomyxoma Peritonei according to GeneCards Suite gene sharing:

(show all 20)
# Super pathways Score Top Affiliating Genes
1
Disease 66
Show member pathways
 13.6 TP53 MUC6 MUC5AC MUC16 MUC1 KRAS
2
fMLP Pathway 64
Show member pathways
 12.58 TP53 KRAS GNAS CTNNB1 CDH1
3
WNT Signaling 64
12.25 TP53 GNAS CTNNB1 CDH1
4
Cytoskeletal Signaling 3
12.25 MUC1 KRT7 KRT20 EPCAM CDH1
5
O-linked glycosylation of mucins 66
Show member pathways
 12.2 MUC6 MUC5AC MUC16 MUC1
6
Development EGFR signaling pathway 22
Show member pathways
 12.14 TP53 MUC1 KRAS CTNNB1 CDH1
7
CLEC7A (Dectin-1) signaling 66
Show member pathways
 12.13 KRAS MUC1 MUC16 MUC5AC MUC6
8
Epithelial to mesenchymal transition in colorectal cancer 74
11.98 CDH1 CTNNB1 KRAS TP53
9
Integrated breast cancer pathway 74
11.91 TP53 KRAS CTNNB1 CDH1
10
Diseases associated with O-glycosylation of proteins 66
Show member pathways
 11.87 MUC6 MUC5AC MUC16 MUC1
11
G12-G13 in Cellular Signaling 64
11.86 KRAS CTNNB1 CDH1
12
Gastrin signaling pathway 74
11.81 KRAS CTNNB1 CDH1
13
DNA damage response (only ATM dependent) 74
11.75 TP53 KRAS CTNNB1
14
Head and neck squamous cell carcinoma 74
11.58 TP53 KRAS CTNNB1
15
Colorectal Cancer Metastasis 64
11.57 TP53 KRAS GNAS CTNNB1 CDH1
16
Termination of O-glycan biosynthesis 66
Show member pathways
 11.3 MUC6 MUC5AC MUC16 MUC1
17
Bladder cancer 74
11.23 TP53 KRAS CDH1
18
Adhesion 3
11.19 REG4 MUC1 EPCAM CTNNB1 CEACAM5 CDH1
19
H19 action Rb-E2F1 signaling and CDK-Beta-catenin activity 74
10.72 CTNNB1 CDH1
20
Mammary gland development pathway - Involution (Stage 4 of 4) 74
10.56 TP53 CDH1
Sources

GO Terms for Pseudomyxoma Peritonei

About this section

Cellular components related to Pseudomyxoma Peritonei according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 lateral plasma membrane GO:0016328 9.73 EPCAM CTNNB1 CDH1
2 flotillin complex GO:0016600 9.46 CTNNB1 CDH1
3 Golgi lumen GO:0005796 9.28 MUC6 MUC5AC MUC2 MUC16 MUC1
4 mucus layer GO:0070701 9.13 MUC5AC MUC2

Biological processes related to Pseudomyxoma Peritonei according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription from RNA polymerase II promoter in response to stress GO:0036003 9.46 TP53 MUC1
2 cellular response to indole-3-methanol GO:0071681 9.26 CTNNB1 CDH1
3 hair follicle placode formation GO:0060789 8.8 GNAS CTNNB1
Sources

Sources for Pseudomyxoma Peritonei

About this section
2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....